Abstract
Sintilimab in combination with gemcitabine and platinum-based chemotherapy has shown good efficacy in a randomized, double-blind, phase 3 study in Chinese patients with squamous NSCLC (ORIENT 12). This subgroup analysis assessed the efficacy of sintilimab combination stratified by key baseline patient characteristics (PD-L1 expression level and disease staging).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
